Clinical

With the comment period ending today, the proposed CMS cuts to radiation oncology reimbursement rates might have a substantial impact on community treatment centers.

Cancer drug cost troubles in the UK prompt NHS to slash its list of approved-for-use oncology products.

For individuals who have not made the sort of risk-averse decisions in their lives that lead to better jobs and wealth accumulation, making treatment decisions after a cancer diagnosis can be very difficult, said Amy Davidoff, PhD, MS, senior research scientist in public health at the Yale School of Public Health

Urologists analyzing data from prostate cancer patients suggest wait and watch in well-informed low-risk prostate cancer patients.

Predictive modeling determined that the needle exchange in Washington, DC, prevented 120 new cases of HIV in 2 years, according to researchers.

The top managed care news this week included draft guidance to reign in the controversial 340B drug program and the top pharmacy benefit managers made it clear they are looking for price discounts for the PCSK9 inhibitors.

Study provides proof that a child's genetic makeup can provide actionable information to alter cancer treatment regimens.

Patients age 65 years and older who are hospitalized for the flu can benefit from the use of early antiviral treatment, according to a new report from the CDC. The early use of flu antiviral medications reduces hospital length of stay and risk of needing extended care after discharge.

Novartis has announced that Zarxio will be available at 15% of the cost of its reference product Neupogen.

Men are opting for preventive breast surgery when diagnosed with unilateral invasive disease, a study published in JAMA Surgery has found.

When treatments get in the marketplace and are being recommended and used, there are actually still a lot of questions that can only be answered by researching real-world data, explained Joe V. Selby, MD, MPH, executive director of the Patient-Centered Outcomes Research Institute.

Personalized telephone counseling and tailored educational materials can improve colonoscopy rates among at-risk family members of patients with colorectal cancer.

Rolapitant was approved to prevent delayed phase chemotherapy-induced nausea and vomiting in adult patients.

Although Repatha and Praluent, the first of a new class of cholesterol-lowering drugs, come with a hefty price in the United States, they will cost 50% to 60% less in Europe.

While it's exciting to see more and more physicians wanting to participate in clinical, they need a little background, support, and infrastructure to do so, said Robert Gabbay, MD, PhD, chief medical officer and senior vice president of Joslin Diabetes Center.

The Cancer Prevention and Ethics Committees of the American Society of Clinical Oncology have made several recommendations that address genetic and genomic testing policies for cancer risk assessment.

The submission by BMS includes results from the ELOQUENT-2 trial that were recently published in the New England Journal of Medicine.

A novel microRNA gene signature could guide earlier intervention in pancreatic cancer.

An expert panel of ASCO developed recommendations for advanced lung cancer treatment after reviewing published literature.

Only about one-fourth of all patients with behavioral health issues are diagnosed by a primary care provider and receive the appropriate treatment, said Paul Ciechanowski, MD, MPH.

When measuring quality of pediatric care, hospitals should include different-hospital readmission along with same-hospital readmission, the authors conclude.

The study published in JNCI has identified CES2 expression as a predictor of response to FOLFIRINOX.

With 1 biosimilar already approved in the US, the FDA has finally released draft guidelines for naming these new products.

While the shift to cancer becoming more of a chronic disease does not have a huge change on the approach of the payer, there are some new challenges to address, said Jennifer Malin, MD, medical director for oncology at Anthem.

Published in the journal Neurology, the study identified childhood cancer, along with hypertension and age, as a risk factor for recurrent stroke.